Replimune Group (REPL) Insider Trading & Ownership $11.37 -0.65 (-5.41%) As of 02:33 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Replimune Group (NASDAQ:REPL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$1.01 M Get REPL Insider Trade Alerts Want to know when executives and insiders are buying or selling Replimune Group stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address REPL Insider Buying and Selling by Quarter Ad Paradigm Press Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Replimune Group Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/16/2024Sushil PatelCEOSell10,000$12.42$124,200.00 11/18/2024Konstantinos XynosInsiderSell7,246$10.78$78,111.88 8/16/2024Emily Luisa HillCFOSell8,938$10.18$90,988.84 6/7/2024Konstantinos XynosInsiderSell15,881$7.50$119,107.50 5/16/2024Andrew SchwendenmanCAOSell2,298$6.47$14,868.06 5/16/2024Christopher SarchiInsiderSell2,218$6.47$14,350.46 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/16/2024Colin LoveCOOSell17,615$6.47$113,969.05 5/16/2024Philip Astley-SparkeChairmanSell37,928$6.47$245,394.16 5/16/2024Robert CoffinDirectorSell11,464$6.47$74,172.08 5/16/2024Sushil PatelCEOSell20,194$6.47$130,655.18 (Data available from 1/1/2013 forward) REPL Insider Trading Activity - Frequently Asked Questions Who is on Replimune Group's Insider Roster? The list of insiders at Replimune Group includes Andrew Schwendenman, Christopher Sarchi, Colin Love, Emily Luisa Hill, Fund Iv L.P. Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel, and Tanya Lewis. Learn more on insiders at REPL. What percentage of Replimune Group stock is owned by insiders? 8.80% of Replimune Group stock is owned by insiders. Learn more on REPL's insider holdings. Which Replimune Group insiders have been selling company stock? The following insiders have sold REPL shares in the last 24 months: Andrew Schwendenman ($14,868.06), Christopher Sarchi ($14,350.46), Colin Love ($308,457.80), Emily Luisa Hill ($90,988.84), Jean M Franchi ($204,885.55), Konstantinos Xynos ($277,077.34), Pamela Esposito ($938,999.58), Philip Astley-Sparke ($568,525.26), Robert Coffin ($74,172.08), Sushil Patel ($535,983.93), and Tanya Lewis ($309,411.60). How much insider selling is happening at Replimune Group? Insiders have sold a total of 254,916 Replimune Group shares in the last 24 months for a total of $3,337,720.50 sold. Replimune Group Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Compensation: $1.07MDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Compensation: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Compensation: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer 1 recent tradesDr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Compensation: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Compensation: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Compensation: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Xenon Pharmaceuticals Insider Trades Zai Lab Insider Trades Merus Insider Trades Twist Bioscience Insider Trades Bausch Health Companies Insider Trades ACADIA Pharmaceuticals Insider Trades Gemini Therapeutics Insider Trades Janux Therapeutics Insider Trades Vericel Insider Trades SpringWorks Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop BuyingAppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? This page (NASDAQ:REPL) was last updated on 1/7/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.